Spyre Therapeutics (SYRE) said late Monday it has priced a public offering of about 14.9 million shares at $18.50 each for expected gross proceeds of $275 million.
The company granted the underwriters a 30-day option to purchase up to about 2.2 million additional shares.
The offering is expected to close Wednesday.